XML 33 R24.htm IDEA: XBRL DOCUMENT
v3.23.1

Segment and Geographic Information | 6 Months Ended
--- | ---
Mar. 31, 2023
Segment Reporting [Abstract] |
Segment and Geographic Information | 14. Segment and Geographic Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker. The Company operates in two reportable segments: the Life Sciences Products segment and the Life Sciences Services segment. These reportable segments also represent the Company’s operating segments. The Company previously operated in three reportable segments: the Semiconductor Solutions Group segment, the Life Sciences Products segment, and the Life Sciences Services segment. The Company’s Life Sciences Products segment provides automated cold storage solutions for biological and chemical compound samples. The Company’s storage systems provide reliable automation and sample inventory management at temperatures down to -190°C and can store anywhere from one to millions of samples. The Company’s sample management solutions include consumable vials and tubes, polymerase chain reaction (PCR), plates, instruments for supporting workflows, and informatics. This portfolio provides customers with the highest level of sample quality, security, availability, intelligence, and integrity throughout the lifecycle of samples providing customers with complete end-to-end “cold-chain of custody” capabilities. The Company also provides controlled rate thawing devices for customers in the medical, biotech and pharmaceutical industries. On October 3, 2022, the Company acquired B Medical, a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to people in more than 150 countries worldwide. On February 2, 2023, the Company acquired Ziath a leading provider of 2D barcode readers for life sciences applications. Both of the acquired businesses are part of the Company’s Life Sciences Products segment. ​ The Company’s Life Sciences Services business is a leading provider of solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research and development markets. The Company processes millions of samples every year, each containing valuable information that must be delivered or preserved with the sample. The Company’s genomic services provide a broad capability to customers for sequencing and synthesis of genes. The Company’s sample management services include off-site storage services, transport services, laboratory services, and interactive informatics solutions. The storage services include short- and long-term sample storage and management of the “cold chain of custody” from collection, to storage, to retrieving the sample which ultimately may go back into the research workflow. The Company considers adjusted operating income, which excludes charges related to amortization of completed technology, the purchase accounting impact on inventory, amortization of other intangible assets, restructuring related charges, contingent consideration fair value adjustments, tariff adjustment, other unallocated corporate expenses, as the primary performance metric when evaluating the business. The following is the summary of the financial information for the Company’s reportable segments for the three and six months ended March 31, 2023 and 2022 (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Three Months Ended March 31, | ​ | Six Months Ended March 31, | ​
​ | ​ | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022 | ​
Revenue: |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | ​
Life Sciences Products | ​ | ​ | $ | 58,860 | ​ | $ | 53,615 | ​ | $ | 148,520 | ​ | $ | 103,487 | ​
Life Sciences Services | ​ | ​ |  | 89,541 | ​ |  | 91,929 | ​ |  | 178,247 | ​ |  | 181,709 | ​
Total revenue | ​ | ​ | $ | 148,401 | ​ | $ | 145,544 | ​ | $ | 326,767 | ​ | $ | 285,196 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income / (loss): | ​ | ​ |  | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Life Sciences Products | ​ | ​ | $ | (16,404) | ​ | $ | 5,288 | ​ | $ | (20,202) | ​ | $ | 9,679 | ​
Life Sciences Services | ​ | ​ |  | (4,878) | ​ |  | 4,856 | ​ |  | (9,490) | ​ |  | 12,740 | ​
Reportable segment operating income (loss) | ​ | ​ | ​ | (21,282) | ​ | ​ | 10,144 | ​ | ​ | (29,692) | ​ | ​ | 22,419 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of completed technology | ​ | ​ | ​ | 4,901 | ​ | ​ | 1,840 | ​ | ​ | 9,070 | ​ | ​ | 3,613 | ​
Purchase accounting impact on inventory | ​ | ​ | ​ | 2,912 | ​ | ​ | — | ​ | ​ | 5,781 | ​ | ​ | — | ​
Amortization of other intangible assets | ​ | ​ | ​ | 7,509 | ​ | ​ | 6,047 | ​ | ​ | 14,882 | ​ | ​ | 12,319 | ​
Restructuring charges | ​ | ​ | ​ | 1,499 | ​ | ​ | 122 | ​ | ​ | 2,961 | ​ | ​ | 295 | ​
Contingent consideration - fair value adjustments | ​ | ​ | ​ | (17,145) | ​ | ​ | — | ​ | ​ | (17,145) | ​ | ​ | — | ​
Tariff adjustment | ​ | ​ | ​ | — | ​ | ​ | (486) | ​ | ​ | — | ​ | ​ | (486) | ​
Other unallocated corporate expenses | ​ | ​ | ​ | (7,981) | ​ | ​ | 7,329 | ​ | ​ | (4,579) | ​ | ​ | 11,711 | ​
Total operating income (loss) | ​ | ​ | ​ | (12,977) | ​ | ​ | (4,708) | ​ | ​ | (40,662) | ​ | ​ | (5,033) | ​
Interest income | ​ | ​ | ​ | 10,394 | ​ | ​ | 3,076 | ​ | ​ | 21,059 | ​ | ​ | 3,111 | ​
Interest expense | ​ | ​ | ​ | — | ​ | ​ | (1,555) | ​ | ​ | — | ​ | ​ | (2,010) | ​
Loss on extinguishment of debt | ​ | ​ | ​ | — | ​ | ​ | (632) | ​ | ​ | — | ​ | ​ | (632) | ​
Other income (expense) | ​ | ​ | ​ | (2,668) | ​ | ​ | (1,170) | ​ | ​ | (1,523) | ​ | ​ | (2,248) | ​
(Loss) before income taxes | ​ | ​ | $ | (5,251) | ​ | $ | (4,989) | ​ | $ | (21,126) | ​ | $ | (6,812) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | Life Sciences Products | ​ | ​ | Life Sciences Services | ​ | ​ | Total | ​
March 31, 2023 | ​ | ​ | ​ | ​ | ​ | $ | 948,580 | ​ | $ | 849,018 | ​ | $ | 1,797,598 | ​
September 30, 2022 | ​ | ​ | ​ | ​ | ​ |  | 378,790 | ​ | ​ | 849,603 | ​ |  | 1,228,393 | ​
​ The following is a reconciliation of the Company’s reportable segments’ segment assets to the corresponding amounts presented in the accompanying unaudited Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, |  | September 30,
​ | ​ | 2023 | ​ | 2022
Segment assets |  | $ | 1,797,598 |  | $ | 1,228,393
Cash and cash equivalents, restricted cash, and marketable securities | ​ |  | 1,451,703 | ​ |  | 2,305,081
Deferred tax assets | ​ |  | 490 | ​ |  | 1,169
Other assets | ​ | ​ | 23 | ​ | ​ | 181,479
Total assets | ​ | $ | 3,249,814 | ​ | $ | 3,716,122
​ Revenue from external customers is attributed to geographic areas based on locations in which customer orders are placed. Net revenue by geographic area for the three and six months ended March 31, 2023 and 2022 (in thousands) are as follows: ​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Three Months Ended March 31, | ​ | ​ | Six Months Ended March 31, | ​ | ​
​ |  | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022 | ​ | ​
Geographic Location: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
North America | ​ | $ | 87,484 | ​ | $ | 94,283 | ​ | $ | 176,419 | ​ | $ | 184,366 | ​ | ​
Rest of Europe | ​ | ​ | 21,432 | ​ | ​ | 19,745 | ​ | ​ | 60,854 | ​ | ​ | 40,028 | ​ | ​
Africa | ​ | ​ | 8,627 | ​ | ​ | 672 | ​ | ​ | 25,837 | ​ | ​ | 1,219 | ​ | ​
China | ​ | ​ | 11,979 | ​ | ​ | 13,757 | ​ | ​ | 25,387 | ​ | ​ | 26,798 | ​ | ​
Asia Pacific/ Other | ​ | ​ | 13,090 | ​ | ​ | 10,278 | ​ | ​ | 27,068 | ​ | ​ | 17,664 | ​ | ​
United Kingdom | ​ | ​ | 5,789 | ​ | ​ | 6,809 | ​ | ​ | 11,202 | ​ | ​ | 15,121 | ​ | ​
Total | ​ | $ | 148,401 | ​ | $ | 145,544 | ​ | $ | 326,767 | ​ | $ | 285,196 | ​ | ​
​ Revenue for the United States comprises 99% of the revenue for North America for each of the three and six months ended March 31, 2023 and 2022.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration